Aerpio Pharmaceuticals (OTCMKTS:ARPO) and Athenex (NASDAQ:ATNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.
This table compares Aerpio Pharmaceuticals and Athenex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
0.4% of Aerpio Pharmaceuticals shares are held by institutional investors. Comparatively, 31.5% of Athenex shares are held by institutional investors. 38.6% of Aerpio Pharmaceuticals shares are held by company insiders. Comparatively, 18.8% of Athenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Aerpio Pharmaceuticals and Athenex’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Athenex||$89.10 million||10.55||-$117.44 million||($1.44)||-9.74|
Aerpio Pharmaceuticals has higher earnings, but lower revenue than Athenex.
This is a breakdown of current ratings and recommmendations for Aerpio Pharmaceuticals and Athenex, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aerpio Pharmaceuticals presently has a consensus price target of $9.25, suggesting a potential upside of 789.42%. Athenex has a consensus price target of $20.40, suggesting a potential upside of 45.51%. Given Aerpio Pharmaceuticals’ higher possible upside, analysts clearly believe Aerpio Pharmaceuticals is more favorable than Athenex.
Aerpio Pharmaceuticals beats Athenex on 5 of the 9 factors compared between the two stocks.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.